MTC-001 is under clinical development by Metcela and currently in Phase I for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase I drugs for Congestive Heart Failure (Heart Failure) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MTC-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTC-001 overview
MTC-001 is under development for the treatment of chronic ischemic heart failure. The drug candidate constitutes of VCAM-1-positive cardiac fibroblasts. MTC-001, combines VCFs and a specialized catheter system for target delivery of the cells to the heart.
Metcela overview
Metcela is a clinical-stage biotech company providing patients with an alternative treatment option for heart disease. The company research and develops autologous and tissue-specific cell therapy for ischemic heart failure. It also develops fibroblasts tissue called VCAM-1-positive Cardiac Fibroblasts (VCF). The company collaborates with other research institutions to develop new product pipelines with advanced cell therapy-related technologies. Its pipeline product include MTC001. Metcela is headquartered in Kawasaki, Kanagawa, Japan.
For a complete picture of MTC-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
